华东医药 - Financials

华东医药 — Financial Statements

Annual Quarterly

5 10 All

Income Statement

Balance Sheet

Cash Flow

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
+Revenue	41.9B	40.6B	37.7B	34.6B	33.7B
Revenue Growth %	3.2%	7.7%	9.1%	2.6%	--
Total Revenue	41.9B	40.6B	37.7B	34.6B	33.7B
Cost Of Revenue	28.0B	27.5B	25.7B	24.0B	22.6B
+Gross Profit	13.9B	13.2B	12.0B	10.6B	11.1B
Gross Margin %	33.2%	32.4%	31.9%	30.7%	33.1%
Total Operating Cost	37.6B	37.1B	34.6B	31.8B	30.7B
Selling Expenses	6.4B	6.6B	6.3B	5.4B	6.0B
Admin Expenses	1.4B	1.4B	1.2B	1.2B	999.0M
Rd Expenses	1.4B	1.3B	1.0B	980.0M	927.0M
Finance Expenses	22.3M	51.2M	78.3M	22.1M	34.2M
+Operating Income	4.3B	3.5B	3.1B	2.9B	3.5B
Operating Margin %	10.3%	8.5%	8.1%	8.3%	10.3%
Non Operating Income	88.0M	50.5M	7.6M	2.7M	12.5M
Non Operating Expenses	111.0M	37.5M	37.9M	30.9M	35.7M
Investment Income	-129.0M	-220.0M	-142.0M	-96.3M	-27.5M
Fair Value Change Income	--	-13.8M	28.5M	--	--
Asset Disposal Income	-5.5M	4.3M	8.3M	-31,600	323.0M
Asset Impairment Loss	41.0M	6.5M	3.8M	16.9M	4.5M
Other Income	200.0M	172.0M	92.8M	175.0M	192.0M
Income Before Tax	4.3B	3.5B	3.0B	2.8B	3.5B
Income Tax	807.0M	620.0M	498.0M	489.0M	544.0M
+Net Income	3.5B	2.8B	2.5B	2.3B	2.9B
Net Margin %	8.3%	7.0%	6.7%	6.8%	8.6%
Net Income Attributable	3.5B	2.8B	2.5B	2.3B	2.8B
Minority Interest	-17.9M	7.5M	33.4M	37.0M	89.9M
Eps Basic	2.00	1.62	1.43	1.32	1.61
Eps Diluted	2.00	1.62	1.43	1.32	1.61

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash And Equivalents	5.3B	4.7B	4.0B	4.0B	3.2B
Trading Financial Assets	--	--	--	--	--
Accounts Receivable	8.4B	7.5B	7.2B	6.4B	6.1B
Notes Receivable	10.7M	6.8M	8.4M	--	--
Notes And Accounts Receivable	8.4B	7.5B	7.2B	6.4B	6.1B
Prepayments	400.0M	279.0M	500.0M	275.0M	251.0M
Inventory	4.8B	4.3B	4.5B	4.0B	4.1B
Total Current Assets	21.1B	18.5B	17.6B	15.5B	14.7B
Long Term Equity Investment	1.5B	1.5B	1.7B	985.0M	850.0M
Fixed Assets	--	4.1B	4.0B	3.1B	2.4B
Fixed Assets Total	4.4B	4.1B	4.0B	3.1B	2.4B
Construction In Progress	--	913.0M	873.0M	1.6B	2.2B
Construction In Progress Total	837.0M	913.0M	873.0M	1.6B	2.2B
Intangible Assets	3.6B	2.3B	2.3B	2.2B	1.5B
Long Term Deferred Expenses	22.6M	20.1M	16.5M	12.4M	8.8M
Total Non Current Assets	16.8B	15.0B	13.6B	11.5B	9.5B
Total Assets	37.9B	33.5B	31.2B	27.0B	24.2B
Short Term Borrowings	2.3B	822.0M	948.0M	1.2B	1.4B
Accounts Payable	4.5B	4.4B	4.9B	3.8B	3.9B
Advance Receipts	1.1M	1.4M	1.2M	1.1M	951,900
Contract Liabilities	174.0M	135.0M	146.0M	118.0M	94.4M
Total Current Liabilities	13.8B	10.8B	10.2B	9.3B	8.6B
Long Term Borrowings	14.3M	521.0M	1.1B	139.0M	152.0M
Total Non Current Liabilities	521.0M	1.1B	1.9B	789.0M	388.0M
Total Liabilities	14.3B	11.9B	12.0B	10.1B	9.0B
Paid In Capital	1.8B	1.8B	1.8B	1.8B	1.8B
Capital Reserve	2.6B	2.4B	2.4B	2.2B	2.2B
Surplus Reserve	1.4B	1.3B	1.2B	1.0B	862.0M
Retained Earnings	17.5B	15.7B	13.5B	11.6B	9.9B
Minority Equity	504.0M	535.0M	599.0M	362.0M	560.0M
Equity Attributable	23.1B	21.0B	18.6B	16.6B	14.6B
Total Equity	23.6B	21.6B	19.2B	16.9B	15.2B

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash From Sales	43.4B	43.6B	40.0B	37.7B	36.2B
Tax Refunds Received	11.6M	60.8M	47.6M	56.0M	21.4M
Total Operating Cash Inflow	45.0B	44.2B	40.6B	38.3B	37.1B
Cash Paid For Goods	28.2B	27.7B	26.4B	25.6B	23.4B
Cash Paid To Employees	4.8B	3.9B	3.1B	2.6B	2.3B
Taxes Paid	2.6B	2.6B	3.1B	1.6B	2.2B
Total Operating Cash Outflow	41.2B	40.2B	38.3B	35.1B	33.7B
Operating Cash Flow	3.7B	3.9B	2.4B	3.2B	3.4B
Total Investing Cash Inflow	327.0M	243.0M	122.0M	252.0M	386.0M
Total Investing Cash Outflow	2.5B	2.0B	2.6B	2.2B	2.1B
Investing Cash Flow	-2.2B	-1.8B	-2.4B	-2.0B	-1.7B
Cash From Borrowings	4.6B	4.7B	4.7B	2.1B	2.2B
Dividends And Interest Paid	1.7B	614.0M	579.0M	463.0M	656.0M
Debt Repayments	3.6B	5.4B	4.3B	2.3B	2.3B
Total Financing Cash Inflow	5.3B	5.1B	5.1B	2.3B	2.2B
Total Financing Cash Outflow	6.0B	6.5B	5.2B	3.0B	2.9B
Financing Cash Flow	-750.0M	-1.4B	-99.7M	-767.0M	-726.0M
Net Change In Cash	782.0M	791.0M	-163.0M	423.0M	926.0M
Ending Cash Balance	5.0B	4.2B	3.4B	3.6B	3.2B
Capex	1.7B	1.6B	1.2B	819.0M	1.5B